RPRX — Royalty Pharma plc
$63.86+0.17%
Last close: · regular session
Last 60 sessions
RPRX closed at $63.86 (+0.17%) on Oct 23, 2026. Float: 389.9M shares. Latest SEC filing: SCHEDULE 13D/A on Aug 17, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for RPRX in the TickerWise workspace.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 75
- Website: https://www.royaltypharma.com
Latest SEC filings for RPRX
Latest RPRX news
- Royalty Pharma declares $0.235 dividend Read article
- Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 Read article
- Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again Read article
- Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.